Print Email

MASCC Member Publications on Nausea and Vomiting

To submit your CINV publication for mascc.org, contact: Alexander Molassiotis, RN,MSc, PhD - United Kingdom


Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM.  Lancet Oncol. 2015 Aug 10. [Epub ahead of print] 

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. 
Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID. Lancet Oncol. 2015 Aug 10.  [Epub ahead of print]

Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Rapoport B, Chua D, Poma A, Arora S, Wang Y, Fein LE.
Support Care Cancer. 2015 May 5. [Epub ahead of print] 

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
Hesketh P, Rossi G, Rizzi G, Palmas, M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ.  Ann Oncol. 2014;25:1340–1346. Free full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071755/.

A phase 3 study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) over repeated cycles of chemotherapy. 
Gralla R, Bosnjak S, Honsta A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K. A phase 3 study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) over repeated cycles of chemotherapy. Ann Oncol. 2014;25:1333–1339. Free full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071753/.

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. 
Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwrtzberg L, Grunberg S. Ann Oncol. 2014;25:1328- 1333. Free full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071754/.

The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: Assessment of Nausea in Chemotherapy Research (ANCHoR), a randomised controlled trial.
Molassiotis A, Russell W, Hughes J, Breckons M, Lloyd-Williams M, Richardson J, Hulme C, Brearley S, Campbell M, Garrow A, Ryder W.
Health Technol Assess. 2013 Jun;17(26):1-114. doi: 10.3310/hta17260.

Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting.
Molassiotis A, Stamataki Z, Kontopantelis E.
Support Care Cancer. 2013 Oct;21(10):2759-67. doi: 10.1007/s00520-013-1843-2.

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).
Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F; PEER investigators.
Ann Oncol. 2012 Aug;23(8):1986-92.

An exploratory study to clarify the cluster of symptoms predictive of chemotherapy-related nausea using random forest modeling.
Molassiotis A, Farrell C, Bourne K, Brearley SG, Pilling M.
J Pain Symptom Manage. 2012 Nov;44(5):692-703.

The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life.
Farrell C, Brearley SG, Pilling M, Molassiotis A.
Support Care Cancer. 2013 Jan;21(1):59-66.

Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice.
Molassiotis A, Brearley SG, Stamataki Z.
Support Care Cancer. 2011 Jul;19(7):949-56.

Understanding the concept of chemotherapy-related nausea: the patient experience.
Molassiotis A, Stricker CT, Eaby B, Velders L, Coventry PA.
Eur J Cancer Care. 2008 Sep;17(5):444-53.

A review of patient self-report tools for chemotherapy-induced nausea and vomiting.
Brearley SG, Clements CV, Molassiotis A. Support Care Cancer. 2008 Nov;16(11):1213-29.

A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre.
Molassiotis A, Saunders MP, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C.
Support Care Cancer. 2008 Feb;16(2):201-8.

The effects of P6 acupressure in the prophylaxis of chemotherapy-related nausea and vomiting in breast cancer patients.
Molassiotis A, Helin AM, Dabbour R, Hummerston S.
Complement Ther Med. 2007 Mar;15(1):3-12.